Related Experiment Video

Updated: Aug 22, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

S Chan1

  • 1The City Hospital, Nottingham NG5 1PB, UK. schan2@ncht.trent.nhs.uk

British Journal of Cancer
|September 15, 2004
PubMed

Insights

Targeting the mTOR pathway with drugs like rapamycin shows promise for treating cancers driven by PI3K/Akt signaling. These inhibitors cause cell cycle arrest, offering a new avenue in oncology research and development.

Area of Science:

  • Molecular Biology
  • Cellular Biology
  • Oncology

Background:

  • The mechanistic target of rapamycin (mTOR) is a key regulator in the PI3K/Akt signaling pathway, controlling fundamental cellular processes.
  • These processes include cell proliferation, survival, migration, and angiogenesis, which are often dysregulated in cancer.

Purpose of the Study:

  • To review the fundamental structure of the PI3K/Akt/mTOR pathway.
  • To examine the role of mTOR in cancer development.
  • To discuss the clinical efficacy of mTOR-targeting agents in cancer therapy.

Main Methods:

  • Literature review of the PI3K/Akt/mTOR pathway.
  • Analysis of clinical studies investigating mTOR inhibitors for cancer treatment.

Main Results:

  • mTOR acts as a crucial downstream mediator in the PI3K/Akt pathway, influencing cell growth and survival.
  • Rapamycin and its analogues (e.g., CCI-779, RAD001, AP23573) antagonize mTOR function, inhibiting downstream signaling.
  • This inhibition leads to cell cycle arrest in the G1 phase, suggesting therapeutic potential.

Conclusions:

  • The PI3K/Akt/mTOR pathway is implicated in various cancers due to its role in cell proliferation and survival.
  • mTOR inhibitors demonstrate potential as a targeted cancer therapy, particularly for tumors with hyperactive PI3K/Akt/mTOR signaling.
  • Targeting mTOR represents an exciting and challenging frontier in oncology research and drug development.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...